¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, ÇüÅ À¯Çüº°, ¿ëµµ À¯Çüº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Pharmaceutical Contract Packaging Market Size Study, by Product Type, by Form Type, by Application Type and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1527275
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 285 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ÀǾàǰ À§Å¹ Æ÷Àå ½ÃÀåÀº 2023³â¿¡ ¾à 61¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ 2024-2032³â¿¡´Â 7.5% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
ÀǾàǰ ¼öŹ Æ÷ÀåÀº ÀǾàǰ Æ÷Àå °øÁ¤À» Àü¹® Á¦3ÀÚ ±â¾÷¿¡ À§Å¹ÇÏ¿© ºí¸®½ºÅÍ ÆÐÅ·, º´ Æ÷Àå, ¶óº§¸µ, 2Â÷ Æ÷Àå µîÀÇ ¼ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾àȸ»ç´Â ±ÔÁ¦±âÁØÀÇ Áؼö¸¦ È®º¸ÇÏ¸é¼ ÀǾàǰ °³¹ßÀ̳ª ¸¶ÄÉÆÃ µîÀÇ ÇÙ½É ¾÷¹«¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. À§Å¹ Æ÷Àå¾÷ÀÚ´Â Æ÷Àå ±â¼ú, ǰÁú °ü¸® ¹× °ø±Þ¸Á °ü¸®¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» Á¦°øÇÏ¿© ºñ¿ë Àý°¨, È¿À²¼º Çâ»ó ¹× À¯Åë ÇÁ·Î¼¼½º Àü¹Ý¿¡ °ÉÃÄ Á¦Ç°ÀÇ ¾ÈÀü°ú ¹«°á¼ºÀ» º¸ÀåÇÕ´Ï´Ù.
½ÅÈï±¹ÀÇ Ç°Áú ¿ä°ÇÀÇ ¾ö°ÝÈ¿Í ÀǾàǰ Æ÷ÀåÀÇ ¼öʾ÷ÀÚ¿¡ ´ëÇÑ ¾Æ¿ô¼Ò½Ì Áõ°¡°¡ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÇ °ßÀοªÀÌ µÉ Àü¸ÁÀÔ´Ï´Ù. Á¦¾à ȸ»ç´Â Àüü »ý»ê ºñ¿ëÀ» ÁÙÀÌ°í ½ÃÀå Ãâ½Ã¸¦ °¡¼ÓÈÇϱâ À§ÇØ Æ÷Àå ÀÛ¾÷À» À§Å¹ Æ÷Àå ¾÷ü¿¡ ¾Æ¿ô¼Ò½ÌÇÕ´Ï´Ù. À̰ÍÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, »ç³»¿¡ ÆÐŰ¡ ´É·Â, Àü¹® Áö½Ä, ¿¹»êÀÇ Á¦¾àÀÌ ¾ø´Â °ÍÀÌ, ÀÌ ¾÷°èÀÇ ¼Ò±Ô¸ð Á¦¾àȸ»ç°¡ Á÷¸éÇÏ´Â ÁÖ¿äÇÑ ¹®Á¦ÀÔ´Ï´Ù. À§Å¹ Æ÷Àå ¼ºñ½º Á¦°ø ¾÷ü´Â Àú·ÅÇÑ ºñ¿ëÀ¸·Î ¼ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¼Ò±Ô¸ð ±â¾÷ÀÇ ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ´Â È¿°úÀûÀÎ Á¢±Ù¹ýÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÚ¿ø°ú ¿¹»êÀÌ ºÎÁ·Çϱ⠶§¹®¿¡ ¸¹Àº ¼Ò±Ô¸ð Á¦¾à ȸ»ç´Â Æ÷Àå ¼öŹ ±â°ü(CPO) ¹× °³¹ß ¹× Á¦Á¶ ¼öŹ ±â°ü(CDMO)°ú »óÈ£ À¯ÀÍÇÑ °ü°è¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. °è¾à ¼ºñ½º Á¦°ø¾÷ü´Â °í°´ÀÇ ±â´ë¿¡ ºÎÀÀÇÏ¿© °íµµ·Î Á¤±³ÇÑ Æ÷Àå Àåºñ¸¦ Á¦°øÇϱâ À§ÇØ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è Á¦¾à »ê¾÷ÀÇ ¼ºÀåÀÌ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æ÷Àå ¾÷¹« ¾Æ¿ô¼Ò½Ì¿¡´Â °í±Þ ÆÐŰ¡ ±â¼ú¿¡ ´ëÇÑ ¾×¼¼½º, È¿À²¼º Çâ»ó, ÇÙ½É ºÐ¾ß¿¡ ÁýÁß, ¼÷·ÃµÈ ¸®¼Ò½º¿¡ ´ëÇÑ ¾×¼¼½º, º¸´Ù ºü¸£°í ¿ì¼öÇÑ ¼ºñ½º µî ¿©·¯ °¡Áö ÀÌÁ¡ÀÌ Àֱ⠶§¹®¿¡ Á¦¾à ȸ»ç´Â CPO ¹× CDMO¿¡ ´ëÇÑ Æ÷Àå ¼ºñ½ºÀÇ ¾Æ¿ô¼Ò½ÌÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù.
¹Ì±¹ÀÇ Drug Supply Chain Security Act(DSCSA) ¹× EUÀÇ Falsified Medicines Derivative(FMD) µîÀÇ Á÷·Äȸ¦ ½Ç½ÃÇÔÀ¸·Î½á ÀǾàǰ Æ÷Àå¿¡ ¹ÙÄڵ尡 Àǹ«ÈµÇ¾î ÀǾàǰ °ø±Þ¿¡ ÀÖ¾î¼ ´ë·®ÀÇ µ¥ÀÌÅͰ¡ Àü¼ÛµÇ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î Á¦Á¶ ±â¾÷Àº ÀÌ »õ·Î¿î ¹ý±Ô¿¡ ´ëÀÀÇϱâ À§ÇÑ ÀûÀýÇÑ ÀÎÇÁ¶ó¸¦ ±¸ÃàÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. Á÷·ÄÈÀÇ ¼Ò°³´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¼ú Çõ½Å, Àα¸ Áõ°¡, °Ç° ÀǽÄ, ÷´Ü Á¦Á¶ ±â¼ú µµÀÔ, °øÁß º¸°Ç ½Ã½ºÅÛÀÇ ÁöÃâ Áõ°¡, Àü¿°º´ °¨¿°À» ¾ïÁ¦Çϱâ À§ÇÑ Á¤ºÎÀÇ »õ·Î¿î ±ÔÁ¦ µµÀÔ µîÀÌ ¼ºÀåÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¹ÙÀÌ¿ÀÁ¦Ç°À̳ª À¯ÀüÀÚ¡¤¼¼Æ÷Ä¡·á µîÀÇ »õ·Î¿î Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Á¦¾àȸ»çÀÇ ÆÇ¸ÅÃËÁø¿¡ µµ¿òÀÌ µÇ°í ÀÖ¾î ÀÌ·¯ÇÑ Æ÷ÀåÁ¦Ç° ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â °è¾àÀ» ÅëÇØ È¿°úÀûÀÎ ÀǾàǰ Æ÷Àå ¼Ö·ç¼ÇÀÇ ¼¼°è ¼ö¿äÀÇ °ÅÀÇ 1/3À» »ý»êÇÔÀ¸·Î½á ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ¹Ì±¹¿¡¼¸¸ »ý»êµÈ ÃÑ ¸ÅÃâÀº ºÏ¹Ì ÃÑ »ç¾÷ÀÇ ¾à 90%·Î ¹àÇôÁ³½À´Ï´Ù. ¹Ì±¹¿¡ º»»ç¸¦ µÐ CPO¿Í CDMO°¡ Á¦°øÇÏ´Â °íǰÁú ¼ºñ½º´Â ÀÌ ³ª¶óÀÇ ÀǾàǰ Æ÷Àå À§Å¹ ¼ºñ½º ¹× ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû ¿ä¹ý ¼ö¿ä, ¾ö°ÝÇÑ ÇÁ·ÎÅäÄÝ Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡µµ ¼¼°è ÀǾàǰ À§Å¹ Æ÷Àå ½ÃÀå ±Ô¸ð¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡´Â ¼ö¸¹Àº ¼öŹ Æ÷Àå ¼ºñ½º Á¦°ø¾÷ü°¡ Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº Á¦¾à ±â¾÷ Áõ°¡ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ½Ã¼³ È®Àå¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Àεµ µî ½ÅÈï±¹À¸·ÎÀÇ ÀǾàǰ Á¦Á¶ ¾Æ¿ô¼Ò½ÌÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à
- ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- Á¦Ç° À¯Çüº°
- ÇüÅ À¯Çüº°
- ¿ëµµº°
- ÁÖ¿ä µ¿Çâ
- °æ±â ÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦2Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚÀÇ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼úÀÇ Áøº¸
- ȯ°æ¿¡ÀÇ ¹è·Á
- ¼ÒºñÀÚÀÇ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó³âµµ
- ȯÀ² º¯È¯À²
Á¦3Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ǰÁú ¿ä°ÇÀÇ ¾ö°ÝÈ
- Á¦¾à ¾÷°èÀÇ ¼ºÀå
- Á¦³×¸¯ ÀǾàǰ ¼ö¿ä
- ½ÃÀåÀÇ °úÁ¦
- ÀÚ»ç Æ÷Àå ´É·ÂÀÇ ºÎÁ·
- ¼Ò±Ô¸ð Á¦¾àȸ»çÀÇ ¿¹»ê Á¦¾à
- ½ÃÀå ±âȸ
- Æ÷Àå¿¡ ÀÖ¾î¼ÀÇ ±â¼ú Çõ½Å
- ¹ÙÀÌ¿À Á¦Ç°°ú »õ·Î¿î Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
Á¦4Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ±â¾÷ÀÇ Çù»ó·Â
- ±¸¸ÅÀÚÀÇ Çù»ó·Â
- ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°-2022-2032
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå Á¦Ç° À¯Çüº° ¼öÀÍ µ¿Ç⠺м®, 2022-2032
- ¿¬Æ÷Àå
- ÇÃ¶ó½ºÆ½ ¶Ç´Â À¯¸® ¿ë±â
- ĸ ¶Ç´Â Ŭ·ÎÀú
Á¦6Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÇüÅ À¯Çüº°-2022-2032
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ÇüÅ À¯Çüº° ¼öÀÍ µ¿Ç⠺м®, 2022-2032
Á¦7Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµ À¯Çüº°-2022-2032
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ¿ëµµ À¯Çüº° ¼öÀÍ µ¿Ç⠺м®, 2022-2032
- ¿ÀŸÄÚÀÌµå ¹× °ü·Ã ÀǾàǰ
- ÇÇÀÓ¾à
- È£¸£¸ó º¸ÃæÁ¦
- ½ÉÇ÷°ü Ä¡·áÁ¦
- ¾Ï Ä¡·áÁ¦
Á¦8Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø :Áö¿ªº°-2022-2032
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Catalent Pharma Solutions
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¸§)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Patheon
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer Centre Source
- Daito Pharmaceutical
- Nipro Corporation
- Becton Dickinson & Company
- AptarGroup Inc.
- Drug Plastics Group
Á¦10Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
JHS
¿µ¹® ¸ñÂ÷
The Global Pharmaceutical Contract Packaging Market is valued approximately at USD 6.1 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2024-2032. Pharmaceutical contract packaging involves outsourcing the packaging process of pharmaceutical products to specialized third-party companies, which provide services such as blister packing, bottling, labelling, and secondary packaging. This allows pharmaceutical companies to focus on core activities like drug development and marketing while ensuring compliance with regulatory standards. Contract packagers offer expertise in packaging technology, quality control, and supply chain management, helping to reduce costs, enhance efficiency, and ensure product safety and integrity throughout the distribution process.
Increasing stringent quality requirements and outsourcing of pharmaceutical packaging to contract packagers in emerging countries are expected to drive the market over the forecast period. Pharmaceutical companies are outsourcing the packaging activities to contract packagers to reduce the overall cost of production and speed to market. This is anticipated to contribute to the growth of the market over the forecast period. In addition, lack of in-house packaging capabilities, expertise, and budget constraints are the major issues faced by small pharmaceutical companies in the industry. Contract packaging service providers are recognized as an effective approach to curb such issues of the small companies owing to the low-cost service offering. However, lack of resources and budgets has prompted many small pharmaceutical companies to establish mutually beneficial relationships with Contract Packaging Organizations (CPOs) and Contract Development and Manufacturing Organizations (CDMOs). Contract service providers are making significant attempts to meet their client's expectations and provide highly sophisticated packaging facilities. Moreover, the growing pharmaceutical industry across the globe is anticipated to drive the market. As outsourcing of packaging activities offers several benefits such as access to advanced packaging technologies, increased efficiency, focus on core areas, access to skilled resources, and faster and better services, pharmaceutical companies are increasingly outsourcing the wrapping services to the CPOs and CDMOs.
The implementation of serialization including the Drug Supply Chain Security Act (DSCSA) in the U.S. and the EU Falsified Medicines Derivative (FMD) has mandated the barcodes on pharmaceutical packaging and the transfer of large volumes of data in the supply of medicines. This has made manufacturing companies develop appropriate infrastructure to comply with this new legislation. The introduction of serialization is expected to drive the market over the forecast period. Technological innovations, population increase, health awareness, the implementation of advanced manufacturing techniques, higher spending in public health systems, and the government implementation of new regulations to control the transmission of contagious diseases are all contributing factors to the growth. Furthermore, the growing demand for bio-products and new treatments such as gene and cell therapies are helpful to promote the pharmaceutical companies thereby increasing the demand for such packaging products.
North America accounts for the leading market share by generating almost one-third of the global demand for effective pharmaceutical packaging solutions through contracts. The total revenue generated by the United States alone was figured out to be around 90% of the total business in North America. Quality services offered by the CPOs and CDMOs based in the United States propel the demand for pharmaceutical contract packaging services and solutions in the country. The demand for biological therapies, increase in strict protocols, and rise in the geriatric population could also broaden the global pharma contract packaging market size. However, Asia Pacific is expected to witness the fastest growth over the forecast period due to the presence of a large number of contract packaging service providers in the region. These players are focusing on expanding their facilities to satisfy the growing needs of pharmaceuticals companies. In addition, increasing the outsourcing of pharmaceutical manufacturing to emerging countries such as India is further driving the growth of the market in the region.
Major market players included in this report are:
- Catalent Pharma Solutions
- Patheon
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer Centre Source
- Daito Pharmaceutical
- Nipro Corporation
- Becton Dickinson & Company
- AptarGroup Inc.
- Drug Plastics Group
- Gerresheimer AG
- Schott AG
- Owens Illinois Inc.
- WestRock Company SGD S.A.
- International Paper Company
The detailed segments and sub-segment of the market are explained below:
By Product Type:
- Flexible Packaging
- Plastic or Glass Containers
- Caps or Closures
By Form Type:
By Application Type:
- Autacoids & Related Drugs
- Contraceptives
- Hormone Replacement
- Cardiovascular Medicines
- Cancer Therapies
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Pharmaceutical Contract Packaging Market Executive Summary
- 1.1. Global Pharmaceutical Contract Packaging Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product Type
- 1.3.2. By Form Type
- 1.3.3. By Application Type
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Pharmaceutical Contract Packaging Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Pharmaceutical Contract Packaging Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increasing Stringent Quality Requirements
- 3.1.2. Growing Pharmaceutical Industry
- 3.1.3. Demand for Generic Pharmaceuticals
- 3.2. Market Challenges
- 3.2.1. Lack of In-house Packaging Capabilities
- 3.2.2. Budget Constraints for Small Pharmaceutical Companies
- 3.3. Market Opportunities
- 3.3.1. Technological Innovations in Packaging
- 3.3.2. Rising Demand for Bio-products and New Treatments
Chapter 4. Global Pharmaceutical Contract Packaging Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Product Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Pharmaceutical Contract Packaging Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Flexible Packaging
- 5.2.2. Plastic or Glass Containers
- 5.2.3. Caps or Closures
Chapter 6. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Form Type 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Pharmaceutical Contract Packaging Market: Form Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oral
- 6.2.2. Injectable
Chapter 7. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Application Type 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Pharmaceutical Contract Packaging Market: Application Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Autacoids & Related Drugs
- 7.2.2. Contraceptives
- 7.2.3. Hormone Replacement
- 7.2.4. Cardiovascular Medicines
- 7.2.5. Cancer Therapies
Chapter 8. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Region 2022-2032
- 8.1. North America Pharmaceutical Contract Packaging Market
- 8.1.1. U.S. Pharmaceutical Contract Packaging Market
- 8.1.1.1. Product Type breakdown size & forecasts, 2022-2032
- 8.1.1.2. Form Type breakdown size & forecasts, 2022-2032
- 8.1.1.3. Application Type breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Pharmaceutical Contract Packaging Market
- 8.2. Europe Pharmaceutical Contract Packaging Market
- 8.2.1. UK Pharmaceutical Contract Packaging Market
- 8.2.2. Germany Pharmaceutical Contract Packaging Market
- 8.2.3. France Pharmaceutical Contract Packaging Market
- 8.2.4. Spain Pharmaceutical Contract Packaging Market
- 8.2.5. Italy Pharmaceutical Contract Packaging Market
- 8.2.6. Rest of Europe Pharmaceutical Contract Packaging Market
- 8.3. Asia Pacific Pharmaceutical Contract Packaging Market
- 8.3.1. China Pharmaceutical Contract Packaging Market
- 8.3.2. India Pharmaceutical Contract Packaging Market
- 8.3.3. Japan Pharmaceutical Contract Packaging Market
- 8.3.4. Australia Pharmaceutical Contract Packaging Market
- 8.3.5. South Korea Pharmaceutical Contract Packaging Market
- 8.3.6. Rest of Asia Pacific Pharmaceutical Contract Packaging Market
- 8.4. Latin America Pharmaceutical Contract Packaging Market
- 8.4.1. Brazil Pharmaceutical Contract Packaging Market
- 8.4.2. Mexico Pharmaceutical Contract Packaging Market
- 8.4.3. Rest of Latin America Pharmaceutical Contract Packaging Market
- 8.5. Middle East & Africa Pharmaceutical Contract Packaging Market
- 8.5.1. Saudi Arabia Pharmaceutical Contract Packaging Market
- 8.5.2. South Africa Pharmaceutical Contract Packaging Market
- 8.5.3. Rest of Middle East & Africa Pharmaceutical Contract Packaging Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Catalent Pharma Solutions
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Patheon
- 9.3.3. Baxter BioPharma Solutions
- 9.3.4. AbbVie Contract Manufacturing
- 9.3.5. Pfizer Centre Source
- 9.3.6. Daito Pharmaceutical
- 9.3.7. Nipro Corporation
- 9.3.8. Becton Dickinson & Company
- 9.3.9. AptarGroup Inc.
- 9.3.10. Drug Plastics Group
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
°ü·ÃÀÚ·á